Aarti Industries Analyst Review 2027: Record EBITDA, 30% Volume Growth and a Target Gap From ₹476 to ₹565
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
Aarti Industries Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹474.50
- 52-Week High / Low: ₹551.75 / ₹338.05
- Market Capitalisation: ₹17,203 crore
- P/E Ratio vs Industry P/E: 29.0 vs 33.4
- Latest Quarter (Q2 FY27) Revenue: ₹3,887 crore (gross)
- Latest Quarter (Q2 FY27) Net Profit: ₹169 crore
Quick Answer: The Aarti Industries analyst review 2027 is split on price but not on direction. PL Capital rates it Accumulate with a ₹476 target, almost exactly the 16 November close of ₹474.50, while ICICI Direct has a Buy at ₹565. Q2 FY27 brought the highest quarterly EBITDA in the company’s history at ₹418 crore, with profit up 59% to ₹169 crore on over 30% volume growth. The years of heavy capex are now starting to pay back, which is what both houses are watching.
After several years of falling profits, the Aarti Industries analyst review 2027 finally has a record quarter to work with. For investors weighing the Aarti Industries share price target 2027, the September 2026 quarter delivered the company’s highest-ever EBITDA of ₹418 crore, a 59% jump in profit and the start-up of its long-awaited Zone IV plant. Brokerages agree the turn is real. They disagree on how much is left in the price.
Aarti Industries is one of India’s largest makers of benzene-based specialty chemicals. Its profit fell from ₹1,186 crore in FY22 to ₹331 crore in FY25 as Chinese competition and weak demand hit chemical prices. The stock, now at ₹474.50, is up about 40% from its 52-week low.
Click Here – Get Free Investment Predictions
What Analysts Are Saying in the Aarti Industries Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| PL Capital (Prabhudas Lilladher) | Accumulate | ₹476 | November 2026 |
| ICICI Direct (ICICI Securities) | Buy | ₹565 | August 2026 |
PL Capital’s view came right after the Q2 FY27 results, under the headline that Zone IV expansion will drive growth. Its target sits at the current price, so it signals a hold-and-add stance rather than a big upside call. ICICI Direct wrote in August that the company is moving from heavy capital spending toward earnings monetisation, and that higher utilisation of expanded capacity could arrive as early as Q2 FY27, which it did.
So the Aarti Industries analyst review 2027 turns on one question: how fast can new capacity fill up and lift returns?
Q2 FY27 Results in the Aarti Industries Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from Operations (gross) | ₹3,887 crore | ₹2,250 crore | +72.8% |
| EBITDA | ₹418 crore | ₹291 crore | +43.6% |
| Profit Before Tax | ₹204 crore | ₹93 crore | +119% |
| Net Profit | ₹169 crore | ₹106 crore | +59.4% |
Volumes rose over 30%, the main driver of growth. Revenue rose even faster, by 54% from the June quarter, as the energy and fuel additives business scaled up. That business brings large revenue on thin margins, which is why the EBITDA margin slipped to about 10.7% even as EBITDA hit a record.
Profit before tax more than doubled. Depreciation and interest have been heavy because of years of capex, so every extra rupee of EBITDA now flows more directly to the bottom line. That operating payoff is what the Aarti Industries analyst review 2027 is built around.
How Aarti Industries Makes Money
An Aarti Industries share analysis starts with benzene. The company turns benzene and toluene into intermediates through several connected value chains:
- Nitro Chloro Benzene (NCB): A base for agrochemicals, dyes and pharma ingredients.
- Dichloro Benzene (DCB): Used in polymers, high-performance plastics and agrochemicals.
- Phenylenediamines: Used in rubber chemicals, polymers and dyes.
- Nitro Toluene: Feeds agrochemical, pharma and pigment makers.
- Energy and fuel additives: A newer, high-volume business that lifted Q2 revenue.
Integration is the moat in the Aarti Industries analyst review 2027. Because products flow from one chain into the next, the company can sell to many end industries and shift output as demand changes. Customers include global agrochemical, pharma and polymer majors, often on long-term contracts. The pharma business was demerged earlier into Aarti Pharmalabs, and surfactants into Aarti Surfactants, so today’s company is a focused specialty chemicals play.
Growth Triggers in the Aarti Industries Analyst Review 2027
Zone IV ramp-up: Phase I was commissioned in September 2026. As utilisation rises, fixed costs get spread over more output.
Capex payback: The company spent ₹1,100 to ₹1,400 crore a year on capex from FY22 to FY26. With the big projects done, cash flow can start to improve.
Augene Chemicals JV: The joint venture was expected to be commissioned in Q2 FY27, with a meaningful financial contribution within two to four quarters.
China plus one: Global buyers want a second source outside China, and Indian chemical makers with scale benefit most.
Key Risks in the Aarti Industries Analyst Review 2027
- Chinese pricing: Low-priced exports from China have crushed margins before and could again.
- Margin dilution: Fast growth in low-margin fuel additives can keep overall margins down.
- Debt: Debt to equity has crept up from 0.58 in FY23 to about 0.83, and interest costs remain high.
- Utilisation delays: If new plants fill slowly, returns stay weak.
- Demand cycles: Agrochemical destocking or a global slowdown hits volumes quickly.
Explore Specialty Chemical Stocks on the Univest Screener
Aarti Industries Analyst Review 2027: Stock at a Glance
| Parameter | Value |
|---|---|
| Market Cap | ₹17,203 crore |
| P/E (TTM) / Industry P/E | 29.0 / 33.4 |
| Price to Book | 2.75 |
| Return on Equity | 9.5% |
| Debt to Equity | 0.83 |
| Dividend Yield | 0.21% |
| FY26 Revenue / Net Profit | ₹8,291 crore / ₹419 crore |
The P/E ratio of 29 is below the chemical industry’s 33.4, but return on equity of 9.5% is still low. The bull case in the Aarti Industries analyst review 2027 is that ROE climbs as earnings recover on an asset base that is already built. Peers such as Atul face similar pressures from Chinese supply.
Shareholding Trend
| Holder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters | 42.18% | 42.14% | 42.09% | 41.82% | 41.82% |
| FIIs | 6.40% | 6.69% | 7.38% | 6.99% | 6.96% |
| DIIs | 18.21% | 18.22% | 20.12% | 21.11% | 20.89% |
| Public | 33.20% | 32.95% | 30.40% | 30.07% | 30.32% |
Domestic institutions raised their stake by more than 2.5 points in the year to September 2026, while retail holding fell about 3 points. Promoter holding dipped slightly. In the Aarti Industries analyst review 2027, that shift shows mutual funds positioning early for a recovery.
What to Watch After the Aarti Industries Analyst Review 2027
- Q3 FY27 results (around late January 2027): Whether EBITDA stays above ₹400 crore.
- Zone IV utilisation: Management commentary on how fast Phase I fills.
- Augene JV contribution: First revenue and profit from the joint venture.
- Chinese chemical prices: Any fresh price war in benzene derivatives.
- Debt reduction: Lower capex should let the company cut borrowing.
Final Word on the Aarti Industries Analyst Review 2027
The Aarti Industries analyst review 2027 captures a company coming out of a long downturn. Record EBITDA, 30% volume growth and a doubling of pre-tax profit in the Q2 FY27 results show that years of investment are starting to work.
The two verified targets, ₹476 and ₹565, frame the debate. If Zone IV and the JV ramp up as planned and margins hold, the higher target looks reachable. If Chinese pricing returns or utilisation lags, the stock may stay close to PL Capital’s view. The Aarti Industries stock outlook 2027 rests on execution.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
How would you sum up the Aarti Industries analyst review 2027?
The Aarti Industries analyst review 2027 shows PL Capital with an Accumulate rating at ₹476 and ICICI Direct with a Buy at ₹565. Both expect earnings to recover as new capacity fills. PL Capital’s target sits at the current price, while ICICI Direct sees about 19% upside. The difference is how quickly they think returns will improve.
What is the Aarti Industries share price target 2027?
Verified targets range from ₹476 (PL Capital, November 2026) to ₹565 (ICICI Direct, August 2026). Against the 16 November 2026 close of ₹474.50, the range implies little to about 19% upside. ICICI Direct’s view came before the Q2 results. These are third-party opinions that may change.
Which Q2 FY27 numbers drive the Aarti Industries analyst review 2027?
Gross revenue rose 72.8% to ₹3,887 crore and EBITDA grew 43.6% to a record ₹418 crore. Profit before tax jumped 119% to ₹204 crore, and net profit rose 59.4% to ₹169 crore. Volumes grew over 30%. Phase I of the Zone IV project was commissioned in September 2026.
Why did the margin fall when EBITDA hit a record?
The energy and fuel additives business grew fast and brings large revenue on thin margins. That pulled the EBITDA margin down to about 10.7%. In rupee terms, EBITDA still rose 43.6%. Analysts in the Aarti Industries analyst review 2027 focus more on absolute profit than on the margin percentage.
What business model underpins the Aarti Industries analyst review 2027?
The company converts benzene and toluene into specialty intermediates through connected value chains such as nitro chloro benzene, dichloro benzene and phenylenediamines. These go to agrochemical, pharma, dye, polymer and energy customers worldwide. Integration lets it shift output across products. FY26 revenue was ₹8,291 crore.
Which risks stand out in the Aarti Industries analyst review 2027?
Low-priced Chinese exports are the biggest risk, since they hurt margins in earlier years. Debt to equity has risen to about 0.83 after heavy capex. Slow utilisation of new plants would keep returns low. A slowdown in agrochemical demand can also hit volumes quickly.
Which events will shape the Aarti Industries stock outlook 2027?
The Q3 FY27 results, due around late January 2027, will show whether EBITDA holds above ₹400 crore. Zone IV utilisation and the first contribution from the Augene JV are key markers. Movements in Chinese chemical prices are an outside risk to track. Debt reduction as capex falls would also support the Aarti Industries analyst review 2027.